Quick Answer
Artiva Biotherapeutics, Inc. reported Operating Income of -$89.81 million for fiscal year 2025.
Artiva Biotherapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$89.81M | -33.5% |
| 2024 | -$67.28M | -119.4% |
| 2023 | -$30.67M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$22.90M | -24.9% | -0.4% |
| June 30, 2025 | -$22.81M | -40.9% | -2.9% |
| March 31, 2025 | -$22.17M | -53.0% | -20.9% |
| September 30, 2024 | -$18.34M | -269.6% | -13.2% |
| June 30, 2024 | -$16.19M | -36.9% | -11.7% |
| March 31, 2024 | -$14.49M | — | -234.0% |
| September 30, 2023 | $10.81M | — | +191.4% |
| June 30, 2023 | -$11.82M | — | — |
- Artiva Biotherapeutics, Inc. showed a decrease of -33.5% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Artiva Biotherapeutics, Inc.’s operating income has declined by 192.8% (from -$30.67 million to -$89.81 million).
- The most recent figure is from Artiva Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: